{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:06:02Z","timestamp":1786982762341,"version":"build-2736575974"},"reference-count":145,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,12,11]],"date-time":"2015-12-11T00:00:00Z","timestamp":1449792000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s40265-015-0516-5","type":"journal-article","created":{"date-parts":[[2015,12,13]],"date-time":"2015-12-13T03:44:12Z","timestamp":1449978252000},"page":"215-229","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["An Update on Medical Treatment Options for Hidradenitis Suppurativa"],"prefix":"10.1007","volume":"76","author":[{"given":"I. E.","family":"Deckers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. P.","family":"Prens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,11]]},"reference":[{"key":"516_CR1","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMcp1014163","volume":"366","author":"GBE Jemec","year":"2012","unstructured":"Jemec GBE. Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012;366:158\u201364.","journal-title":"N Engl J Med"},{"key":"516_CR2","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1468-3083.2009.03356.x","volume":"23","author":"JE Revuz","year":"2009","unstructured":"Revuz JE. Hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2009;23:985\u201398.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"516_CR3","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","volume":"29","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juh\u00e1sz I, et al. European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa. J Eur Acad Dermatol Venereol. 2015;29:619\u201344.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"516_CR4","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jaad.2014.11.017","volume":"72","author":"IE Deckers","year":"2015","unstructured":"Deckers IE, van der Zee HH, Boer J, Prens EP. Correlation of early-onset hidradenitis suppurativa with stronger genetic susceptibility and more widespread involvement. J Am Acad Dermatol. 2015;72:485\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"516_CR5","doi-asserted-by":"crossref","unstructured":"Bettoli V, Ricci M, Zauli S, Virgili A. Hidradenitis suppurativa\u2013acne inversa: a relevant dermatosis in pediatric age. Br J Dermatol. 2015 (Epub ahead).","DOI":"10.1111\/bjd.13951"},{"key":"516_CR6","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jaad.2012.07.027","volume":"68","author":"I Cosmatos","year":"2013","unstructured":"Cosmatos I, Matcho A, Weinstein R, Montgomery MO, Stang P. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol. 2013;68:412\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"516_CR7","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0190-9622(96)90321-7","volume":"35","author":"GBE Jemec","year":"1996","unstructured":"Jemec GBE, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol. 1996;35:191\u20134.","journal-title":"J Am Acad Dermatol"},{"key":"516_CR8","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.jaad.2008.06.020","volume":"59","author":"JE Revuz","year":"2008","unstructured":"Revuz JE, Canoui-Poitrine F, Wolkenstein P, Viallette C, Gabison G, Pouget F, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case\u2013control studies. J Am Acad Dermatol. 2008;59:596\u2013601.","journal-title":"J Am Acad Dermatol"},{"key":"516_CR9","first-page":"729","volume-title":"Dermatogic Surgery","author":"HJ Hurley","year":"1989","unstructured":"Hurley HJ. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approaches. In: Roenigh R, Roenigh H, editors. Dermatogic Surgery. New York: Marcel Dekker; 1989. p. 729\u201339."},{"key":"516_CR10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1046\/j.1365-2133.2003.05390.x","volume":"149","author":"K Sartorius","year":"2003","unstructured":"Sartorius K, Lapins J, Emtestam L. Jemec GBE. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol. 2003;149:211\u20133.","journal-title":"Br J Dermatol"},{"key":"516_CR11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jaad.2009.02.013","volume":"61","author":"F Canoui-Poitrine","year":"2009","unstructured":"Canoui-Poitrine F, Revuz JE, Wolkenstein P, Viallette C, Gabison G, Pouget F, et al. Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol. 2009;61:51\u20137.","journal-title":"J Am Acad Dermatol"},{"key":"516_CR12","doi-asserted-by":"crossref","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","volume":"157","author":"AB Kimball","year":"2012","unstructured":"Kimball AB, Kerdel F, Adams D, Mrowietz U, Gelfand JM, Gniadecki R, et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med Am Coll Phys. 2012;157:846\u201355.","journal-title":"Ann Intern Med Am Coll Phys."},{"key":"516_CR13","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1365-2133.1990.tb06264.x","volume":"122","author":"C-W Yu","year":"1990","unstructured":"Yu C-W, Cook MG. Hidradenitis suppurativa: a disease of follicular epithelium, rather than apocrine glands. Br J Dermatol. 1990;122:763\u20139.","journal-title":"Br J Dermatol"},{"key":"516_CR14","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1365-2133.1996.tb03880.x","volume":"135","author":"J Boer","year":"1996","unstructured":"Boer J, Weltevreden EF. Hidradenitis suppurativa or acne inversa. A clinicopathological study of early lesions. Br J Dermatol. 1996;135:721\u20135.","journal-title":"Br J Dermatol"},{"key":"516_CR15","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1600-0625.2009.00915.x","volume":"19","author":"M Laffert von","year":"2010","unstructured":"von Laffert M, Helmbold P, Wohlrab J, Fiedler E, Stadie V, Marsch WC. Hidradenitis suppurativa (acne inversa): early inflammatory events at terminal follicles and at interfollicular epidermis. Exp Dermatol. 2010;19:533\u20137.","journal-title":"Exp Dermatol"},{"key":"516_CR16","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2133.2010.10034.x","volume":"164","author":"M Laffert Von","year":"2011","unstructured":"Von Laffert M, Stadie V, Wohlrab J, Marsch WC. Hidradenitis suppurativa\/acne inversa: bilocated epithelial hyperplasia with very different sequelae. Br J Dermatol. 2011;164:367\u201371.","journal-title":"Br J Dermatol"},{"key":"516_CR17","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/j.1365-2133.2011.10254.x","volume":"164","author":"HH Zee van der","year":"2011","unstructured":"van der Zee HH, de Ruiter L, van den Broecke DG, Dik WA, Laman JD, Prens EP. Elevated levels of tumour necrosis factor (TNF)-\u03b1, interleukin (IL)-1\u03b2 and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-\u03b1 and IL-1\u03b2. Br J Dermatol. 2011;164:1292\u20138.","journal-title":"Br J Dermatol"},{"key":"516_CR18","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaad.2010.07.010","volume":"65","author":"C Schlapbach","year":"2011","unstructured":"Schlapbach C, H\u00e4nni T, Yawalkar N, Hunger RE. Expression of the IL-23\/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2011;65:790\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"516_CR19","doi-asserted-by":"crossref","unstructured":"Kelly G, Hughes R, Mc Garry T, van den Born M, Adamzik K, Fitzgerald R, et al. Dysregulated cytokine expression in lesional and non-lesional skin in Hidradenitis suppurativa. Br J Dermatol. 2015 (Epub ahead).","DOI":"10.1111\/bjd.14075"},{"key":"516_CR20","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/bjd.13866","volume":"173","author":"JR Ingram","year":"2015","unstructured":"Ingram JR, McPhee M. Management of hidradenitis suppurativa: a UK survey of current practice. Br J Dermatol. 2015;173:1070\u20132.","journal-title":"Br J Dermatol"},{"key":"516_CR21","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-4362.1983.tb02150.x","volume":"22","author":"OJ Clemmensen","year":"1983","unstructured":"Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol. 1983;22:325\u20138.","journal-title":"Int J Dermatol"},{"key":"516_CR22","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/978-3-540-33101-8_21","volume-title":"Topical treatment. Hidradenitis suppurativa","author":"K Sartorius","year":"2006","unstructured":"Sartorius K, Boer J, Jemec GBE. Topical treatment. Hidradenitis suppurativa. Berlin: Springer; 2006. p. 150\u201360."},{"key":"516_CR23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2230.2009.03377.x","volume":"35","author":"J Boer","year":"2010","unstructured":"Boer J, Jemec GBE. Resorcinol peels as a possible self-treatment of painful nodules in hidradenitis suppurativa. Clin Exp Dermatol. 2010;35:36\u201340.","journal-title":"Clin Exp Dermatol"},{"key":"516_CR24","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/1523-1747.ep12277353","volume":"93","author":"M Detmar","year":"1989","unstructured":"Detmar M, Mayer-da-Silva A, Stadler R, Orfanos CE. Effects of azelaic acid on proliferation and ultrastructure of mouse keratinocytes in vitro. J Invest Dermatol. 1989;93:70\u20134.","journal-title":"J Invest Dermatol"},{"key":"516_CR25","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s13671-013-0064-8","volume":"3","author":"IE Deckers","year":"2014","unstructured":"Deckers IE, van der Zee HH, Prens EP. Epidemiology of hidradenitis suppurativa: prevalence, pathogenesis, and factors associated with the development of HS. Curr Dermatol Rep. 2014;3:54\u201360.","journal-title":"Curr Dermatol Rep."},{"key":"516_CR26","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1159\/000246246","volume":"193","author":"GBE Jemec","year":"1996","unstructured":"Jemec GBE, Faber M, Gutschik E, Wendelboe P. The bacteriology of hidradenitis suppurativa. Dermatology. 1996;193:203\u20136.","journal-title":"Dermatology"},{"key":"516_CR27","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1046\/j.1365-2133.1999.02613.x","volume":"140","author":"J Lapins","year":"1999","unstructured":"Lapins J, Jarstrand C, Emtestam L. Coagulase-negative staphylococci are the most common bacteria found in cultures from the deep portions of hidradentis suppurativa lesions, as obtained by carbon dioxide laser surgery. Br J Dermatol. 1999;140:90\u20135.","journal-title":"Br J Dermatol"},{"key":"516_CR28","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1365-2133.2011.10747.x","volume":"166","author":"K Sartorius","year":"2012","unstructured":"Sartorius K, Killasli H, Oprica C, Sullivan A, Lapins J. Bacteriology of hidradenitis suppurativa exacerbations and deep tissue cultures obtained during carbon dioxide laser treatment. Br J Dermatol. 2012;166:879\u201383.","journal-title":"Br J Dermatol"},{"key":"516_CR29","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2340\/00015555-1841","volume":"94","author":"\u0141 Matusiak","year":"2014","unstructured":"Matusiak \u0141, Bieniek A, Szepietowski JC. Bacteriology of hidradenitis suppurativa\u2014which antibiotics are the treatment of choice? Acta Derm Venereol. 2014;94:699\u2013702.","journal-title":"Acta Derm Venereol"},{"key":"516_CR30","doi-asserted-by":"crossref","unstructured":"Nikolakis G, Join-Lambert O, Karagiannidis I, Guet-Revillet H, Zouboulis CC, Nassif A. Bacteriology of hidradenitis suppurativa\/acne inversa: a review. J Am Acad Dermatol. 2015;73:S12\u20138.","DOI":"10.1016\/j.jaad.2015.07.041"},{"key":"516_CR31","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/exd.12793","volume":"24","author":"HC Ring","year":"2015","unstructured":"Ring HC, Riis Mikkelsen P, Miller IM, Jenssen H, Fuursted K, Saunte DM, et al. The bacteriology of hidradenitis suppurativa: a systematic review. Exp Dermatol. 2015;24:727\u201331.","journal-title":"Exp Dermatol"},{"key":"516_CR32","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.3201\/eid2012.140064","volume":"20","author":"H Guet-Revillet","year":"2014","unstructured":"Guet-Revillet H, Coignard-Biehler H, Jais J-P, Quesne G, Frapy E, Poir\u00e9e S, et al. Bacterial pathogens associated with hidradenitis suppurativa, France. Emerg Infect Dis. 2014;20:1990\u20138.","journal-title":"Emerg Infect Dis."},{"key":"516_CR33","doi-asserted-by":"crossref","unstructured":"Collier F, Smith RC, Morton CA. Diagnosis and management of hidradenitis suppurativa. BMJ. 2013;346:f2121.","DOI":"10.1136\/bmj.f2121"},{"key":"516_CR34","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1086\/426545","volume":"40","author":"TR Pasquale","year":"2005","unstructured":"Pasquale TR, Tan JS. Nonantimicrobial effects of antibacterial agents. Clin Infect Dis. 2005;40:127\u201335.","journal-title":"Clin Infect Dis"},{"key":"516_CR35","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaad.2005.10.004","volume":"54","author":"AN Sapadin","year":"2006","unstructured":"Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54:258\u201365.","journal-title":"J Am Acad Dermatol"},{"key":"516_CR36","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.phrs.2010.10.007","volume":"63","author":"E Monk","year":"2011","unstructured":"Monk E, Shalita A, Siegel DM. Clinical applications of non-antimicrobial tetracyclines in dermatology. Pharmacol Res. 2011;63:130\u201345.","journal-title":"Pharmacol Res"},{"key":"516_CR37","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0190-9622(98)70272-5","volume":"39","author":"GBE Jemec","year":"1998","unstructured":"Jemec GBE, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 1998;39:971\u20134.","journal-title":"J Am Acad Dermatol"},{"key":"516_CR38","first-page":"208","volume":"158","author":"T Simonart","year":"2008","unstructured":"Simonart T, Dramaix M, De Maertelaer V. Efficacy of tetracyclines in the treatment of acne vulgaris: a review. Br J Dermatol. 2008;158:208\u201316.","journal-title":"Br J Dermatol"},{"key":"516_CR39","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1097\/01.AOG.0000216197.26783.b5","volume":"107","author":"GG Nahum","year":"2006","unstructured":"Nahum GG, Uhl K, Kennedy DL. Antibiotic use in pregnancy and lactation: what is and is not known about teratogenic and toxic risks. Obstet Gynecol. 2006;107:1120\u201338.","journal-title":"Obstet Gynecol"},{"key":"516_CR40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/jac\/7.suppl_A.3","volume":"7","author":"DA Leigh","year":"1981","unstructured":"Leigh DA. Antibacterial activity and pharmacokinetics of clindamycin. J Antimicrob Chemother. 1981;7:3\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"516_CR41","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/BF01743360","volume":"24","author":"B Vlem Van","year":"1996","unstructured":"Van Vlem B, Vanholder R, De Paepe P, Ringoir S, Vogelaers D. Immunomodulating effects of antibiotics: literature review. Infection. 1996;24:275\u201391.","journal-title":"Infection"},{"key":"516_CR42","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3109\/08923979209009234","volume":"14","author":"MA Tufano","year":"1992","unstructured":"Tufano MA, Cipollaro de l\u2019Ero G, Ianniello R, Baroni A, Galdlero F. Antimicrobial agents induce monocytes to release IL-1\u03b1, IL-6, and TNF and induce lymphocytes to release IL-4 and TNF\u03c4. Immunopharmacol Immunotoxicol. 1992;14:769\u201382.","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"516_CR43","doi-asserted-by":"crossref","first-page":"S402","DOI":"10.1093\/clinids\/5.Supplement_3.S402","volume":"5","author":"P Sensi","year":"1983","unstructured":"Sensi P. History of the development of rifampin. Rev Infect Dis. 1983;5:S402\u20136.","journal-title":"Rev Infect Dis"},{"key":"516_CR44","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0738-081X(02)00328-0","volume":"21","author":"N Tsankov","year":"2003","unstructured":"Tsankov N, Angelova I. Rifampin in dermatology. Clin Dermatol. 2003;21:50\u20135.","journal-title":"Clin Dermatol"},{"key":"516_CR45","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1179\/joc.2004.16.4.357","volume":"16","author":"HM Ziglam","year":"2004","unstructured":"Ziglam HM, Daniels I, Finch RG. Immunomodulating activity of rifampicin. J Chemother. 2004;16:357\u201361.","journal-title":"J Chemother"},{"key":"516_CR46","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1365-2133.2006.07155.x","volume":"154","author":"CO Mendon\u00e7a","year":"2006","unstructured":"Mendon\u00e7a CO. Griffiths CEM. Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. Br J Dermatol. 2006;154:977\u20138.","journal-title":"Br J Dermatol"},{"key":"516_CR47","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000228334","volume":"219","author":"G Gener","year":"2009","unstructured":"Gener G, Canoui-Poitrine F, Revuz JE, Faye O, Poli F, Gabison G, et al. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology. 2009;219:148\u201354.","journal-title":"Dermatology"},{"key":"516_CR48","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000228337","volume":"219","author":"HH Zee van der","year":"2009","unstructured":"van der Zee HH, Boer J, Prens EP, Jemec GBE. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology. 2009;219:143\u20137.","journal-title":"Dermatology"},{"key":"516_CR49","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/jdv.12127","volume":"28","author":"V Bettoli","year":"2014","unstructured":"Bettoli V, Zauli S, Borghi A, Toni G, Minghetti S, Ricci M, et al. Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa\u2013acne inversa: a prospective study on 23 patients. J Eur Acad Dermatol Venereol. 2014;28:125\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"516_CR50","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0163-4453(93)95367-R","volume":"26","author":"J Renneberg","year":"1993","unstructured":"Renneberg J, Karlsson E, Nilsson B, Walder M. Interactions of drugs acting against Staphylococcus aureus in vitro and in a mouse model. J Infect. 1993;26:265\u201377.","journal-title":"J Infect"},{"key":"516_CR51","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1684\/ejd.2013.2213","volume":"24","author":"O Join-Lambert","year":"2014","unstructured":"Join-Lambert O, Ribadeau-Dumas F, Jullien V, Kitzis M-D, Jais J-P, Coignard-Biehler H, et al. Dramatic reduction of clindamycin plasma concentration in hidradenitis suppurativa patients treated with the rifampin\u2013clindamycin combination. Eur J Dermatol. 2014;24:94\u20135.","journal-title":"Eur J Dermatol."},{"key":"516_CR52","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jinf.2015.03.013","volume":"71","author":"A Bernard","year":"2015","unstructured":"Bernard A, Kermarrec G, Parize P, Caruba T, Bouvet A, Mainardi J-L, et al. Dramatic reduction of clindamycin serum concentration in staphylococcal osteoarticular infection patients treated with the oral clindamycin\u2013rifampicin combination. J Infect. 2015;71:200\u20136.","journal-title":"J Infect."},{"key":"516_CR53","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s15010-015-0773-y","volume":"43","author":"E Curis","year":"2015","unstructured":"Curis E, Pestre V, Jullien V, Eyrolle L, Archambeau D, Morand P, et al. Pharmacokinetic variability of clindamycin and influence of rifampicin on clindamycin concentration in patients with bone and joint infections. Infection. 2015;43:473\u201381.","journal-title":"Infection."},{"key":"516_CR54","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000321716","volume":"222","author":"O Join-Lambert","year":"2011","unstructured":"Join-Lambert O, Coignard H, Jais J, Guet-Revillet H, Poiree S, Fraitag S, et al. Efficacy of rifampin\u2013moxifloxacin\u2013metronidazole combination therapy in hidradenitis suppurativa. Dermatology. 2011;222:49\u201358.","journal-title":"Dermatology."},{"key":"516_CR55","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00003088-199936050-00004","volume":"36","author":"KC Lamp","year":"1999","unstructured":"Lamp KC, Freeman CD, Klutman NE, Lacy MK. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet. 1999;36:353\u201373.","journal-title":"Clin Pharmacokinet."},{"key":"516_CR56","first-page":"393","volume":"66","author":"L Shakir","year":"2011","unstructured":"Shakir L, Javeed A, Ashraf M, Riaz A. Metronidazole and the immune system. Pharmazie. 2011;66:393\u20138.","journal-title":"Pharmazie."},{"key":"516_CR57","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2165\/00003495-200262060-00008","volume":"62","author":"RBR Muijsers","year":"2002","unstructured":"Muijsers RBR, Jarvis B. Moxifloxacin. Drugs. 2002;62:967\u201373.","journal-title":"Drugs"},{"key":"516_CR58","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s15010-005-8209-8","volume":"33","author":"A Dalhoff","year":"2005","unstructured":"Dalhoff A. Immunomodulatory activities of fluoroquinolones. Infection. 2005;33:55\u201370.","journal-title":"Infection."},{"key":"516_CR59","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s10072-015-2260-8","volume":"36","author":"G Ca\u00e7\u00e3o","year":"2015","unstructured":"Ca\u00e7\u00e3o G, Fontes S, Salgado M, Rodrigues T, Dam\u00e1sio J. Metronidazole-induced central and peripheral nervous system toxicity. Neurol Sci. 2015;36:1737\u20139.","journal-title":"Neurol Sci."},{"key":"516_CR60","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/WNF.0b013e3182334b35","volume":"34","author":"A Kuriyama","year":"2011","unstructured":"Kuriyama A, Jackson JL, Doi A, Kamiya T. Metronidazole-induced central nervous system toxicity: a systematic review. Clin Neuropharmacol. 2011;34:241\u20137.","journal-title":"Clin Neuropharmacol."},{"key":"516_CR61","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/00054725-200111000-00008","volume":"7","author":"F Mart\u00ednez","year":"2001","unstructured":"Mart\u00ednez F, Nos P, Benlloch S, Ponce J. Hidradenitis suppurativa and Crohn\u2019s disease: response to treatment with infliximab. Inflamm Bowel Dis. 2001;7:323\u20136.","journal-title":"Inflamm Bowel Dis"},{"key":"516_CR62","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/j.1572-0241.2002.05950.x","volume":"97","author":"KH Katsanos","year":"2002","unstructured":"Katsanos KH, Christodoulou DK, Tsianos EV. Axillary hidradenitis suppurativa successfully treated with infliximab in a Crohn\u2019s disease patient. Am J Gastroenterol. 2002;97:2155\u20136.","journal-title":"Am J Gastroenterol."},{"key":"516_CR63","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jamadermatol.2014.691","volume":"150","author":"JS Kirby","year":"2014","unstructured":"Kirby JS, Miller JJ, Adams DR, Leslie D. Health care utilization patterns and costs for patients with hidradenitis suppurativa. JAMA Dermatol. 2014;150:937\u201344.","journal-title":"JAMA Dermatol."},{"key":"516_CR64","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1001\/archdermatol.2009.49","volume":"145","author":"R Blanco","year":"2009","unstructured":"Blanco R, Mart\u00ednez-Taboada VM, Villa I, Gonz\u00e1lez-Vela MC, Fern\u00e1ndez-Llaca H, Agudo M, et al. Long-term successful adalimumab therapy in severe hidradenitis suppurativa. Arch Dermatol. 2009;145:580\u20134.","journal-title":"Arch Dermatol."},{"key":"516_CR65","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1517\/14740338.2012.633509","volume":"11","author":"TA Kerensky","year":"2012","unstructured":"Kerensky TA, Gottlieb AB, Yaniv S, Au S. Etanercept: efficacy and safety for approved indications. Expert Opin Drug Saf. 2012;11:121\u201339.","journal-title":"Expert Opin Drug Saf."},{"key":"516_CR66","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.1365-2125.2008.03263.x","volume":"66","author":"P Traczewski","year":"2008","unstructured":"Traczewski P, Rudnicka L. Adalimumab in dermatology. Br J Clin Pharmacol. 2008;66:618\u201325.","journal-title":"Br J Clin Pharmacol"},{"key":"516_CR67","doi-asserted-by":"crossref","unstructured":"Mrowietz U, Reich K. Ten years of infliximab: its role in dermatology. Eur J Pharmacol. 2009;623:S10\u20136.","DOI":"10.1016\/j.ejphar.2009.10.024"},{"key":"516_CR68","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1529-8019.2008.01213.x","volume":"22","author":"L Castelo-Soccio","year":"2009","unstructured":"Castelo-Soccio L, Van Voorhees AS. Long-term efficacy of biologics in dermatology. Dermatol Ther. 2009;22:22\u201333.","journal-title":"Dermatol Ther."},{"key":"516_CR69","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","volume":"62","author":"A Grant","year":"2010","unstructured":"Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62:205\u201317.","journal-title":"J Am Acad Dermatol."},{"key":"516_CR70","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3109\/09546634.2012.683767","volume":"23","author":"S Paradela","year":"2012","unstructured":"Paradela S, Rodr\u00edguez-Lojo R, Fern\u00e1ndez-Torres R, Ar\u00e9valo P, Fonseca E. Long-term efficacy of infliximab in hidradenitis suppurativa. J Dermatol Treat. 2012;23:278\u201383.","journal-title":"J Dermatol Treat."},{"key":"516_CR71","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/bjd.12713","volume":"170","author":"B Moriarty","year":"2014","unstructured":"Moriarty B, Jiyad Z, Creamer D. Four-weekly infliximab in the treatment of severe hidradenitis suppurativa. Br J Dermatol. 2014;170:986\u20137.","journal-title":"Br J Dermatol."},{"key":"516_CR72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2009.03389.x","volume":"23","author":"D Pathirana","year":"2009","unstructured":"Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23:1\u201370.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"516_CR73","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jaad.2006.01.024","volume":"55","author":"N Scheinfeld","year":"2006","unstructured":"Scheinfeld N. Treatment of coincident seronegative arthritis and hidradentis supprativa with adalimumab. J Am Acad Dermatol. 2006;55:163\u20134.","journal-title":"J Am Acad Dermatol."},{"key":"516_CR74","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/archderm.142.9.1110","volume":"142","author":"DK Moul","year":"2006","unstructured":"Moul DK, Korman NJ. Severe hidradenitis suppurativa treated with adalimumab. Arch Dermatol. 2006;142:1110\u20132.","journal-title":"Arch Dermatol."},{"key":"516_CR75","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2133.2011.10339.x","volume":"165","author":"I Miller","year":"2011","unstructured":"Miller I, Lynggaard CD, Lophaven S, Zachariae C, Dufour DN, Jemec GBE. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol. 2011;165:391\u20138.","journal-title":"Br J Dermatol."},{"key":"516_CR76","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/j.1365-4632.2010.04545.x","volume":"49","author":"M Amano","year":"2010","unstructured":"Amano M, Grant A, Kerdel FA. A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa. Int J Dermatol. 2010;49:950\u20135.","journal-title":"Int J Dermatol."},{"key":"516_CR77","doi-asserted-by":"crossref","unstructured":"van Rappard DC, Leenarts MFE, Meijerink-van\u2019t Oost L, Mekkes JR. Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa. J Dermatol Treat. 2012;23:284\u20139.","DOI":"10.3109\/09546634.2011.571657"},{"key":"516_CR78","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1365-2133.2007.08372.x","volume":"158","author":"EJ Giamarellos-Bourboulis","year":"2008","unstructured":"Giamarellos-Bourboulis EJ, Pelekanou E, Antonopoulou A, Petropoulou H, Baziaka F, Karagianni V, et al. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol. 2008;158:567\u201372.","journal-title":"Br J Dermatol."},{"key":"516_CR79","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jaad.2008.11.898","volume":"60","author":"RA Lee","year":"2009","unstructured":"Lee RA, Dommasch E, Treat J, Sciacca-Kirby J, Chachkin S, Williams J, et al. A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 2009;60:565\u201373.","journal-title":"J Am Acad Dermatol."},{"key":"516_CR80","first-page":"501","volume":"146","author":"DR Adams","year":"2010","unstructured":"Adams DR, Yankura JA, Fogelberg AC, Anderson BE. Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol. 2010;146:501\u20134.","journal-title":"Arch Dermatol"},{"key":"516_CR81","doi-asserted-by":"crossref","first-page":"425","DOI":"10.4103\/0019-5154.139859","volume":"59","author":"VN Sehgal","year":"2014","unstructured":"Sehgal VN, Pandhi D, Khurana A. Biologics in dermatology: an integrated review. Indian J Dermatol. 2014;59:425\u201341.","journal-title":"Indian J Dermatol."},{"key":"516_CR82","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1468-3083.2011.04123.x","volume":"26","author":"WP Gulliver","year":"2012","unstructured":"Gulliver WP, Jemec GBE, Baker KA. Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2012;26:911\u20134.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"516_CR83","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1136\/annrheumdis-2012-202392","volume":"72","author":"EM Baerveldt","year":"2013","unstructured":"Baerveldt EM, Kappen JH, Thio HB, van Laar JAM, van Hagen PM, Prens EP. Successful long-term triple disease control by ustekinumab in a patient with Beh\u00e7et\u2019s disease, psoriasis and hidradenitis suppurativa. Ann Rheum Dis. 2013;72:626\u20137.","journal-title":"Ann Rheum Dis."},{"key":"516_CR84","doi-asserted-by":"crossref","first-page":"320","DOI":"10.2340\/00015555-1229","volume":"92","author":"VR Sharon","year":"2012","unstructured":"Sharon VR, Garcia MS, Bagheri S, Goodarzi H, Yang C, Ono Y, et al. Management of recalcitrant hidradenitis suppurativa with ustekinumab. Acta Derm Venereol. 2012;92:320\u20131.","journal-title":"Acta Derm Venereol."},{"key":"516_CR85","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.ad.2013.09.011","volume":"105","author":"MI Santos-P\u00e9rez","year":"2014","unstructured":"Santos-P\u00e9rez MI, Garc\u00eda-Rodicio S, del Olmo-Revuelto MA, Pozo-Rom\u00e1n T. Ustekinumab for hidradenitis suppurativa: a case report. Actas Dermosifiliogr. 2014;105:720\u20132.","journal-title":"Actas Dermosifiliogr."},{"key":"516_CR86","unstructured":"Blok JL, Li K, Brodmerkel C, Horv\u00e1tovich P, Jonkman MF, Horv\u00e1th B. Ustekinumab in hidradenitis suppurativa: a clinical open label study with analyses of the protein expression profile in serum. FCO3.8. 23rd European Academy of Dermatology Congress, Amsterdam, Oct 8\u201312, 2014."},{"key":"516_CR87","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/157488412803305821","volume":"7","author":"N Pazyar","year":"2012","unstructured":"Pazyar N, Feily A, Yaghoobi R. An overview of interleukin-1 receptor antagonist, anakinra, in the treatment of cutaneous diseases. Curr Clin Pharmacol. 2012;7:271\u20135.","journal-title":"Curr Clin Pharmacol."},{"key":"516_CR88","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/archdermatol.2010.328","volume":"146","author":"JL Hsiao","year":"2010","unstructured":"Hsiao JL, Antaya RJ, Berger T, Maurer T, Shinkai K, Leslie KS. Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review. Arch Dermatol. 2010;146:1265\u201370.","journal-title":"Arch Dermatol."},{"key":"516_CR89","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1001\/jamadermatol.2013.5377","volume":"149","author":"K Zarchi","year":"2013","unstructured":"Zarchi K, Dufour DN, Jemec GBE. Successful treatment of severe hidradenitis suppurativa with anakinra. JAMA Dermatol. 2013;149:1192\u20134.","journal-title":"JAMA Dermatol."},{"key":"516_CR90","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000343221","volume":"226","author":"HH Zee Van der","year":"2013","unstructured":"Van der Zee HH, Prens EP. Failure of anti-interleukin-1 therapy in severe hidradenitis suppurativa: a case report. Dermatology. 2013;226:97\u2013100.","journal-title":"Dermatology."},{"key":"516_CR91","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/bjd.13292","volume":"172","author":"D Menis","year":"2015","unstructured":"Menis D, Maro\u00f1as-Jim\u00e9nez L, Delgado-Marquez AM, Postigo-Llorente C, Vanaclocha-Sebasti\u00e1n F. Two cases of severe hidradenitis suppurativa with failure of anakinra therapy. Br J Dermatol. 2015;172:810\u20131.","journal-title":"Br J Dermatol."},{"key":"516_CR92","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jaad.2013.09.044","volume":"70","author":"K Leslie","year":"2014","unstructured":"Leslie K, Tripathi S, Nguyen T, Pauli M, Rosenblum M. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa. J Am Acad Dermatol. 2014;70:243\u201351.","journal-title":"J Am Acad Dermatol."},{"key":"516_CR93","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00403-013-1409-7","volume":"306","author":"G Wozel","year":"2014","unstructured":"Wozel G, Blasum C. Dapsone in dermatology and beyond. Arch Dermatol Res. 2014;306:103\u201324.","journal-title":"Arch Dermatol Res."},{"key":"516_CR94","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/09546630600830588","volume":"17","author":"MR Kaur","year":"2006","unstructured":"Kaur MR, Lewis HM. Hidradenitis suppurativa treated with dapsone: a case series of five patients. J Dermatol Treat. 2006;17:211\u20133.","journal-title":"J Dermatol Treat."},{"key":"516_CR95","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1159\/000329023","volume":"222","author":"S Yazdanyar","year":"2011","unstructured":"Yazdanyar S, Boer J, Ingvarsson G, Szepietowski JC, Jemec GBE. Dapsone therapy for hidradenitis suppurativa: a series of 24 patients. Dermatology. 2011;222:342\u20136.","journal-title":"Dermatology."},{"key":"516_CR96","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1084\/jem.20100977","volume":"208","author":"K Ghoreschi","year":"2011","unstructured":"Ghoreschi K, Br\u00fcck J, Kellerer C, Deng C, Peng H, Rothfuss O, et al. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med. 2011;208:2291\u2013303.","journal-title":"J Exp Med."},{"key":"516_CR97","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/bjd.13346","volume":"172","author":"IE Deckers","year":"2015","unstructured":"Deckers IE, Zee HH, Balak DMW, Prens EP. Fumarates, a new treatment option for therapy-resistant hidradenitis suppurativa: a prospective open-label pilot study. Br J Dermatol. 2015;172:828\u20139.","journal-title":"Br J Dermatol."},{"key":"516_CR98","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.jaad.2010.02.063","volume":"63","author":"KT Amor","year":"2010","unstructured":"Amor KT, Ryan C, Menter A. The use of cyclosporine in dermatology: part I. J Am Acad Dermatol. 2010;63:925\u201346.","journal-title":"J Am Acad Dermatol."},{"key":"516_CR99","first-page":"289P","volume":"88","author":"DA Buckley","year":"1995","unstructured":"Buckley DA, Rogers S. Cyclosporin-responsive hidradenitis suppurativa. J R Soc. 1995;88:289P\u201390P.","journal-title":"J R Soc."},{"key":"516_CR100","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1365-2230.2005.01983.x","volume":"31","author":"R Rose","year":"2006","unstructured":"Rose R, Goodfield M, Clark S. Treatment of recalcitrant hidradenitis suppurativa with oral cyclosporin. Clin Exp Dermatol. 2006;31:154\u20135.","journal-title":"Clin Exp Dermatol."},{"key":"516_CR101","doi-asserted-by":"crossref","first-page":"e278","DOI":"10.1016\/j.jaad.2012.06.011","volume":"67","author":"L Bianchi","year":"2012","unstructured":"Bianchi L, Hansel K, Stingeni L. Recalcitrant severe hidradenitis suppurativa successfully treated with cyclosporine A. J Am Acad Dermatol. 2012;67:e278\u20139.","journal-title":"J Am Acad Dermatol."},{"key":"516_CR102","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/978-3-540-33101-8_18","volume-title":"Immunosuppressive therapy in hidradenitis suppurativa. Hidradenitis Suppurativa","author":"H Nyb\u00e6k","year":"2006","unstructured":"Nyb\u00e6k H, Jemec GBE. Immunosuppressive therapy in hidradenitis suppurativa. Hidradenitis Suppurativa. Berlin: Springer; 2006. p. 136\u201340."},{"key":"516_CR103","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jaad.2008.11.911","volume":"60","author":"A Alikhan","year":"2009","unstructured":"Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. 2009;60:539\u201361.","journal-title":"J Am Acad Dermatol."},{"key":"516_CR104","doi-asserted-by":"crossref","unstructured":"Nazary M, Prens EP, Boer J. Azathioprine lacks efficacy in hidradenitis suppurativa: a retrospective study of 9 patients. Br J Dermatol. 2015 (Epub ahead).","DOI":"10.1111\/bjd.14086"},{"key":"516_CR105","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ejim.2010.09.010","volume":"21","author":"G Cocco","year":"2010","unstructured":"Cocco G, Chu DCC, Pandolfi S. Colchicine in clinical medicine. A guide for internists. Eur J Intern Med. 2010;21:503\u20138.","journal-title":"Eur J Intern Med."},{"key":"516_CR106","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000332846","volume":"223","author":"HH Zee Van der","year":"2011","unstructured":"Van der Zee HH, Prens EP. The anti-inflammatory drug colchicine lacks efficacy in hidradenitis suppurativa. Dermatology. 2011;223:169\u201373.","journal-title":"Dermatology."},{"key":"516_CR107","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1586\/1744666X.2015.1026894","volume":"11","author":"O Y\u00e9lamos","year":"2015","unstructured":"Y\u00e9lamos O, Puig L. Systemic methotrexate for the treatment of psoriasis. Expert Rev Clin Immunol. 2015;11:553\u201363.","journal-title":"Expert Rev Clin Immunol."},{"key":"516_CR108","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1046\/j.1365-2230.2002.11125.x","volume":"27","author":"GBE Jemec","year":"2002","unstructured":"Jemec GBE. Methotrexate is of limited value in the treatment of hidradenitis suppurativa. Clin Exp Dermatol. 2002;27:528\u20139.","journal-title":"Clin Exp Dermatol."},{"key":"516_CR109","first-page":"22","volume":"7","author":"SB Nickle","year":"2014","unstructured":"Nickle SB, Peterson N, Peterson M. Updated Physician\u2019s Guide to the off-label uses of oral isotretinoin. J Clin Aesthet Dermatol. 2014;7:22\u201334.","journal-title":"J Clin Aesthet Dermatol."},{"key":"516_CR110","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/S0190-9622(96)90277-7","volume":"34","author":"GBE Jemec","year":"1996","unstructured":"Jemec GBE, Hansen U. Histology of hidradenitis suppurativa. J Am Acad Dermatol. 1996;34:994\u20139.","journal-title":"J Am Acad Dermatol."},{"key":"516_CR111","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2230.1986.tb00512.x","volume":"11","author":"JFB Norris","year":"1986","unstructured":"Norris JFB, Cunliffe WJ. Failure of treatment of familial widespread hidradenitis suppurativa with isotretinoin. Clin Exp Dermatol. 1986;11:579\u201383.","journal-title":"Clin Exp Dermatol."},{"key":"516_CR112","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0190-9622(99)70530-X","volume":"40","author":"J Boer","year":"1999","unstructured":"Boer J, van Gemert MJP. Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa. J Am Acad Dermatol. 1999;40:73\u20136.","journal-title":"J Am Acad Dermatol."},{"key":"516_CR113","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000182261","volume":"218","author":"A Soria","year":"2009","unstructured":"Soria A, Canoui-Poitrine F, Wolkenstein P, Poli F, Gabison G, Pouget F, et al. Absence of efficacy of oral isotretinoin in hidradenitis suppurativa: a retrospective study based on patients\u2019 outcome assessment. Dermatology. 2009;218:134\u20135.","journal-title":"Dermatology."},{"key":"516_CR114","doi-asserted-by":"crossref","unstructured":"Blok JL, van Hattem S, Jonkman MF, Horv\u00e1th B. Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review. Br J Dermatol. 2013;168:243\u201352.","DOI":"10.1111\/bjd.12104"},{"key":"516_CR115","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1517\/14656566.6.10.1725","volume":"6","author":"CS Lee","year":"2005","unstructured":"Lee CS, Koo J. A review of acitretin, a systemic retinoid for the treatment of psoriasis. Expert Opin Pharmacother. 2005;6:1725\u201334.","journal-title":"Expert Opin Pharmacother"},{"key":"516_CR116","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1365-2133.2010.10071.x","volume":"164","author":"J Boer","year":"2011","unstructured":"Boer J, Nazary M. Long-term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a misnomer? Br J Dermatol. 2011;164:170\u20135.","journal-title":"Br J Dermatol."},{"key":"516_CR117","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/bjd.12884","volume":"171","author":"\u0141 Matusiak","year":"2014","unstructured":"Matusiak \u0141, Bieniek A, Szepietowski JC. Acitretin for hidradenitis suppurativa treatment: a prospective series of 17 patients. Br J Dermatol. 2014;171:170\u20134.","journal-title":"Br J Dermatol."},{"key":"516_CR118","first-page":"155","volume":"150","author":"R Verdolini","year":"2015","unstructured":"Verdolini R, Simonacci F, Menon S, Pavlou P, Mannello B. Alitretinoin: a useful agent in the treatment of hidradenitis suppurativa, especially in women of child-bearing age. G Ital Dermatol Venereol. 2015;150:155\u201362.","journal-title":"G Ital Dermatol Venereol."},{"key":"516_CR119","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/j.1468-3083.2010.03934.x","volume":"25","author":"A Brocard","year":"2011","unstructured":"Brocard A, Dr\u00e9no B. Innate immunity: a crucial target for zinc in the treatment of inflammatory dermatosis. J Eur Acad Dermatol Venereol. 2011;25:1146\u201352.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"516_CR120","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000100883","volume":"214","author":"A Brocard","year":"2007","unstructured":"Brocard A, Knol A, Khammari A, Dr\u00e9no B. Hidradenitis suppurativa and zinc: a new therapeutic approach. Dermatology. 2007;214:325\u20137.","journal-title":"Dermatology."},{"key":"516_CR121","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/jdv.12116","volume":"27","author":"D Badr","year":"2013","unstructured":"Badr D, Kurban M, Abbas O. Metformin in dermatology: an overview. J Eur Acad Dermatol Venereol. 2013;27:1329\u201335.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"516_CR122","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/j.1468-3083.2012.04668.x","volume":"27","author":"R Verdolini","year":"2013","unstructured":"Verdolini R, Clayton N, Smith A, Alwash N, Mannello B. Metformin for the treatment of hidradenitis suppurativa: a little help along the way. J Eur Acad Dermatol Venereol. 2013;27:1101\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"516_CR123","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/j.1365-2230.2008.03121.x","volume":"34","author":"B Arun","year":"2009","unstructured":"Arun B, Loffeld A. Long-standing hidradenitis suppurativa treated effectively with metformin. Clin Exp Dermatol. 2009;34:920\u20131.","journal-title":"Clin Exp Dermatol."},{"key":"516_CR124","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1365-2133.1988.tb03227.x","volume":"119","author":"GBE Jemec","year":"1988","unstructured":"Jemec GBE. The symptomatology of hidradenitis suppurativa in women. Br J Dermatol. 1988;119:345\u201350.","journal-title":"Br J Dermatol."},{"key":"516_CR125","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/j.1365-2133.1996.tb07942.x","volume":"134","author":"JH Barth","year":"1996","unstructured":"Barth JH, Layton AM, Cunliffe WJ. Endocrine factors in pre-and postmenopausal women with hidradenitis suppurativa. Br J Dermatol. 1996;134:1057\u20139.","journal-title":"Br J Dermatol."},{"key":"516_CR126","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1517\/14656566.5.4.933","volume":"5","author":"JF Libecco","year":"2004","unstructured":"Libecco JF, Bergfeld WF. Finasteride in the treatment of alopecia. Expert Opin Pharmacother. 2004;5:933\u201340.","journal-title":"Expert Opin Pharmacother."},{"key":"516_CR127","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1046\/j.1365-2133.1999.03224.x","volume":"141","author":"AM Farrell","year":"1999","unstructured":"Farrell AM, Randall VA, Vafaee T. Dawber RPR. Finasteride as a therapy for hidradenitis suppurativa. Br J Dermatol. 1999;141:1136\u201352.","journal-title":"Br J Dermatol."},{"key":"516_CR128","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/09546630510031403","volume":"16","author":"MA Joseph","year":"2005","unstructured":"Joseph MA, Jayaseelan E, Ganapathi B, Stephen J. Hidradenitis suppurativa treated with finasteride. J Dermatol Treat. 2005;16:75\u20138.","journal-title":"J Dermatol Treat."},{"key":"516_CR129","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/jamadermatol.2013.2874","volume":"149","author":"HK Randhawa","year":"2013","unstructured":"Randhawa HK, Hamilton J, Pope E. Finasteride for the treatment of hidradenitis suppurativa in children and adolescents. JAMA Dermatol. 2013;149:732\u20135.","journal-title":"JAMA Dermatol."},{"key":"516_CR130","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1365-2133.1986.tb05741.x","volume":"115","author":"RS Sawers","year":"1986","unstructured":"Sawers RS, Randall VA, Ebling FJ. Control of hidradenitis suppurativa in women using combined antiandrogen (cyproterone acetate) and oestrogen therapy. Br J Dermatol. 1986;115:269\u201374.","journal-title":"Br J Dermatol"},{"key":"516_CR131","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1365-2133.1986.tb05740.x","volume":"115","author":"PS Mortimer","year":"1986","unstructured":"Mortimer PS, Dawber RPR, Gales MA, Moore RA. A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa. Br J Dermatol. 1986;115:263\u20138.","journal-title":"Br J Dermatol."},{"key":"516_CR132","first-page":"20616","volume":"19","author":"N Scheinfeld","year":"2013","unstructured":"Scheinfeld N. Treatment of hidradenitis supprurativa associated pain with nonsteroidal anti-inflammatory drugs, acetaminophen, celecoxib, gabapentin, pegabalin, duloxetine, and venlafaxine. Dermatol Online J. 2013;19:20616.","journal-title":"Dermatol Online J"},{"key":"516_CR133","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jaad.2015.07.046","volume":"73","author":"B Horv\u00e1th","year":"2015","unstructured":"Horv\u00e1th B, Janse IC, Sibbald GR. Pain management in patients with hidradenitis suppurativa. J Am Acad Dermatol. 2015;73:S47\u201351.","journal-title":"J Am Acad Dermatol."},{"key":"516_CR134","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaad.2014.04.001","volume":"71","author":"AMR Schrader","year":"2014","unstructured":"Schrader AMR, Deckers IE, van der Zee HH, Boer J, Prens EP. Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severity. J Am Acad Dermatol. 2014;71:460\u20137.","journal-title":"J Am Acad Dermatol"},{"key":"516_CR135","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1365-2133.2009.09198.x","volume":"161","author":"K Sartorius","year":"2009","unstructured":"Sartorius K, Emtestam L, Jemec GBE, Lapins J. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol. 2009;161:831\u20139.","journal-title":"Br J Dermatol."},{"key":"516_CR136","doi-asserted-by":"crossref","unstructured":"Bettoli V, Naldi L, Cazzaniga S, Zauli S, Atzori L, Borghi A, et al. Overweight, diabetes and disease duration influence clinical severity in Hidradenitis Suppurativa-Acne Inversa. Evidence from the national Italian Registry. Br J Dermatol. 2015. doi: 10.1111\/bjd.13864 (Epub ahead of print).","DOI":"10.1111\/bjd.13864"},{"key":"516_CR137","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/jid.2012.255","volume":"133","author":"BG Vazquez","year":"2013","unstructured":"Vazquez BG, Alikhan A, Weaver AL, Wetter DA, Davis MD. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol. 2013;133:97\u2013103.","journal-title":"J Invest Dermatol"},{"key":"516_CR138","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/ced.12269","volume":"39","author":"CL Thomas","year":"2014","unstructured":"Thomas CL, Gordon KD, Mortimer PS. Rapid resolution of hidradenitis suppurativa after bariatric surgical intervention. Clin Exp Dermatol. 2014;39:315\u20138.","journal-title":"Clin Exp Dermatol."},{"key":"516_CR139","doi-asserted-by":"crossref","unstructured":"Boer J. Resolution of hidradenitis suppurativa after weight loss by dietary measures, especially on frictional locations. J Eur Acad Dermatol Venereol. 2015. doi: 10.1111\/jdv.13059 (Epub ahead of print).","DOI":"10.1111\/jdv.13059"},{"key":"516_CR140","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2340\/00015555-1800","volume":"94","author":"C Kromann","year":"2014","unstructured":"Kromann C, Ibler KS, Kristiansen V, Jemec GB. The Influence of body weight on the prevalence and severity of hidradenitis suppurativa. Acta Derm Venereol. 2014;94:553\u20137.","journal-title":"Acta Derm Venereol"},{"key":"516_CR141","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1001\/jamadermatol.2014.1165","volume":"150","author":"IM Miller","year":"2014","unstructured":"Miller IM, Ellervik C, Vinding GR, Zarchi K, Ibler KS, Knudsen KM, et al. Association of metabolic syndrome and hidradenitis suppurativa. JAMA Dermatol. 2014;150:1273\u201380.","journal-title":"JAMA Dermatol."},{"key":"516_CR142","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jaad.2009.03.043","volume":"61","author":"\u0141 Matusiak","year":"2009","unstructured":"Matusiak \u0141, Bieniek A, Szepietowski JC. Hidradenitis suppurativa and associated factors: still unsolved problems. J Am Acad Dermatol. 2009;61:362\u20135.","journal-title":"J Am Acad Dermatol."},{"key":"516_CR143","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/dth.12251","volume":"28","author":"AA Gaspari","year":"2015","unstructured":"Gaspari AA, Tyring S. New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors. Dermatol Ther. 2015;28:179\u201393.","journal-title":"Dermatol Ther."},{"key":"516_CR144","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1517\/13543784.2013.806483","volume":"22","author":"A Chiricozzi","year":"2013","unstructured":"Chiricozzi A, Krueger JG. IL-17 targeted therapies for psoriasis. Expert Opin Investig Drugs. 2013;22:993\u20131005.","journal-title":"Expert Opin Investig Drugs."},{"key":"516_CR145","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s40265-015-0439-1","volume":"75","author":"ED Deeks","year":"2015","unstructured":"Deeks ED. Apremilast: a review in psoriasis and psoriatic arthritis. Drugs. 2015;75:1393\u2013403.","journal-title":"Drugs."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0516-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-015-0516-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0516-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T21:12:03Z","timestamp":1718226723000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-015-0516-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,11]]},"references-count":145,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["516"],"URL":"https:\/\/doi.org\/10.1007\/s40265-015-0516-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,11]]}}}